UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P0170 Trastuzumab for HER2-positive breast cancer: Experience from a middle-income Asian country

European journal of cancer (1990), 2015-07, Vol.51, p.e32-e33

2015

Volltextzugriff (PDF)

1833 Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country

European journal of cancer (1990), 2015-09, Vol.51, p.S276-S277

2015

Volltextzugriff (PDF)

Comparison of planned and measured rectal dose in-vivo during high dose rate Cobalt-60 brachytherapy of cervical cancer

Physica medica, 2014-12, Vol.30 (8), p.980-984

2014

Volltextzugriff (PDF)

Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer

European journal of cancer care, 2015-11, Vol.24 (6), p.938-944

2015

Volltextzugriff (PDF)

P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series

European journal of cancer (1990), 2014-05, Vol.50, p.e48-e49

2014

Volltextzugriff (PDF)

1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy

European journal of cancer (1990), 2015-09, Vol.51, p.S295-S296

2015

Volltextzugriff (PDF)

OP0005 Performance of predict tool in predicting breast cancer survival in an Asian setting

European journal of cancer (1990), 2014-05, Vol.50, p.e2-e2

2014

Volltextzugriff (PDF)

OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable?

European journal of cancer (1990), 2014-05, Vol.50, p.e2-e3

2014

Volltextzugriff (PDF)

Contralateral Hypertrophy Post Yttrium-90 Transarterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Curēus (Palo Alto, CA), 2024-04

2024

Volltextzugriff (PDF)

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Annals of oncology, 2020-03, Vol.31 (3), p.334-351

2020

Volltextzugriff (PDF)

Radiofrequency ablation followed by resection of malignant liver tumors

The American journal of surgery, 1999-05, Vol.177 (5), p.411-417

1999

Volltextzugriff (PDF)

Transradial Access for Interventional Radiology: Single-Centre Procedural and Clinical Outcome Analysis

Canadian Association of Radiologists journal, 2017-08, Vol.68 (3), p.318-327

2017

Volltextzugriff (PDF)

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Annals of oncology, 2023-03, Vol.34 (3), p.251-261

2023

Volltextzugriff (PDF)

334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1

Annals of oncology, 2022-11, Vol.33, p.S1573

2022

Volltextzugriff (PDF)

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial

Annals of oncology, 2022-11, Vol.33, p.S1582-S1583

2022

Volltextzugriff (PDF)

LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)

Annals of oncology, 2023-11, Vol.34, p.S1486

2023

Volltextzugriff (PDF)

LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial

Annals of oncology, 2023-10, Vol.34, p.S1269-S1269

2023

Volltextzugriff (PDF)

1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study

Annals of oncology, 2023-10, Vol.34, p.S771-S771

2023

Volltextzugriff (PDF)

P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S352-S353

2023

Volltextzugriff (PDF)

652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)

Annals of oncology, 2022-09, Vol.33, p.S840

2022

Volltextzugriff (PDF)

PO-178: A single institutional audit of setup errors for 3DCRT rectal cancers

Radiotherapy and oncology, 2019-12, Vol.141, p.S79-S80

2019

Volltextzugriff (PDF)

513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study

Annals of oncology, 2024-09, Vol.35, p.S434-S434

2024

Volltextzugriff (PDF)

327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

Annals of oncology, 2022-11, Vol.33, p.S1570-S1571

2022

Volltextzugriff (PDF)

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Annals of oncology, 2022-09, Vol.33, p.S1421

2022

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(154)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(120)
Life Sciences & Biomedicine
(88)
Humans
(43)
Male
(27)
Biological And Medical Sciences
(26)
Physical Sciences
(25)
Animals
(20)
Radiology, Nuclear Medicine & Medical Imaging
(19)
Female
(18)
Technology
(18)
Fundamental And Applied Biological Sciences. Psychology
(15)
Middle Aged
(14)
Physics
(13)
Medical Sciences
(12)
Plant Sciences
(12)
Surgery
(12)
Adult
(11)
Chemistry
(11)
Radiology
(11)
Aged
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

P0170 Trastuzumab for HER2-positive breast cancer: Experience from a middle-income Asian country

1833 Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country

Comparison of planned and measured rectal dose in-vivo during high dose rate Cobalt-60 brachytherapy of cervical cancer

Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer

P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series

1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy

OP0005 Performance of predict tool in predicting breast cancer survival in an Asian setting

OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable?

Contralateral Hypertrophy Post Yttrium-90 Transarterial Radioembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Radiofrequency ablation followed by resection of malignant liver tumors

Transradial Access for Interventional Radiology: Single-Centre Procedural and Clinical Outcome Analysis

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1

362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial

LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)

LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial

1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study

P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study

652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)

PO-178: A single institutional audit of setup errors for 3DCRT rectal cancers

513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study

Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial

327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Suchergebnisse filtern